
EquitySector - HealthcareVery High Risk
Regular
NAV (01-Oct-26)
Returns (Since Inception)
Fund Size
₹406 Cr
Expense Ratio
2.59%
ISIN
INF0QA701987
Minimum SIP
₹500
Exit Load
1.00%
Inception Date
27 Dec 2024
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.98%
+17.77% (Cat Avg.)
Since Inception
+7.68%
— (Cat Avg.)
| Equity | ₹389.48 Cr | 95.95% |
| Debt | ₹1.23 Cr | 0.30% |
| Others | ₹15.2 Cr | 3.74% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Divi's Laboratories Ltd | Equity | ₹42.82 Cr | 10.55% |
| Sun Pharmaceuticals Industries Ltd | Equity | ₹33.31 Cr | 8.21% |
| Rubicon Research Ltd | Equity | ₹27.66 Cr | 6.81% |
| Piramal Pharma Ltd | Equity | ₹27.27 Cr | 6.72% |
| Aurobindo Pharma Ltd | Equity | ₹25.09 Cr | 6.18% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹24.34 Cr | 6.00% |
| Torrent Pharmaceuticals Ltd | Equity | ₹20.43 Cr | 5.03% |
| Neuland Laboratories Ltd | Equity | ₹16.66 Cr | 4.11% |
| Emcure Pharmaceuticals Ltd | Equity | ₹15.59 Cr | 3.84% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹13.59 Cr | 3.35% |
| Fortis Healthcare Ltd | Equity | ₹10.9 Cr | 2.69% |
| Zydus Lifesciences Ltd | Equity | ₹10.41 Cr | 2.56% |
| Ipca Laboratories Ltd | Equity | ₹9.97 Cr | 2.46% |
| Laurus Labs Ltd | Equity | ₹9.57 Cr | 2.36% |
| Vijaya Diagnostic Centre Ltd | Equity | ₹9.37 Cr | 2.31% |
| Zydus Wellness Ltd | Equity | ₹9.2 Cr | 2.27% |
| Senores Pharmaceuticals Ltd | Equity | ₹8.73 Cr | 2.15% |
| Clearing Corporation Of India Ltd | Cash - Repurchase Agreement | ₹8.61 Cr | 2.12% |
| Shaily Engineering Plastics Ltd | Equity | ₹8.12 Cr | 2.00% |
| GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹7.26 Cr | 1.79% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹6.88 Cr | 1.70% |
| Dr. Lal PathLabs Ltd | Equity | ₹6.82 Cr | 1.68% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹5.74 Cr | 1.41% |
| Cipla Ltd | Equity | ₹5.64 Cr | 1.39% |
| Bajaj Money Market Dir Gr | Mutual Fund - Open End | ₹5.28 Cr | 1.30% |
| Dr Reddy's Laboratories Ltd | Equity | ₹5.19 Cr | 1.28% |
| Biocon Ltd | Equity | ₹4.72 Cr | 1.16% |
| Navin Fluorine International Ltd | Equity | ₹4 Cr | 0.99% |
| Krishna Institute of Medical Sciences Ltd | Equity | ₹3.78 Cr | 0.93% |
| Turtlemint Fintech Solutions Ltd | Equity | ₹3.74 Cr | 0.92% |
| OneSource Specialty Pharma Ltd | Equity | ₹3.34 Cr | 0.82% |
| Medi Assist Healthcare Services Ltd | Equity | ₹3.31 Cr | 0.82% |
| Jubilant Pharmova Ltd | Equity | ₹3.09 Cr | 0.76% |
| Net Receivables / (Payables) | Cash - Collateral | ₹2.54 Cr | 0.63% |
| MTAR Technologies Ltd | Equity | ₹1.06 Cr | 0.26% |
| Sumitomo Chemical India Ltd Ordinary Shares | Equity | ₹1.03 Cr | 0.25% |
| Neogen Chemicals Ltd | Equity | ₹0.85 Cr | 0.21% |
Large Cap Stocks
31.17%
Mid Cap Stocks
25.52%
Small Cap Stocks
39.26%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹361.48 Cr | 89.05% |
| Basic Materials | ₹14 Cr | 3.45% |
| Consumer Defensive | ₹9.2 Cr | 2.27% |
| Financial Services | ₹3.74 Cr | 0.92% |
| Industrials | ₹1.06 Cr | 0.26% |
Standard Deviation
This fund
--
Cat. avg.
16.08%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.63
Higher the better
ISIN INF0QA701987 | Expense Ratio 2.59% | Exit Load 1.00% | Fund Size ₹406 Cr | Age 1 year 9 months | Lumpsum Minimum ₹500 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹40,430 Cr
Address
8th floor, E-Core,Solitaire Business Hub (formerly Marvel Edge), Viman Nagar 411014
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments